Tesmilifene fumarate

Cat. No.: HY-101179

CAS No.: 1185241-83-1

Molecular Formula: $C_{23}H_{29}NO_5$

Molecular Weight: 399.48

Target: Histamine Receptor

Pathway: GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (625.81 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.5033 mL	12.5163 mL	25.0325 mL
	5 mM	0.5007 mL	2.5033 mL	5.0065 mL
	10 mM	0.2503 mL	1.2516 mL	2.5033 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (5.21 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (5.21 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (5.21 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Tesmilifene fumarate (DPPE fumarate), an H_{1C} receptor antagonist, potentiates a wide range of cytotoxics and even to offer some protection of normal cells[1][2].

In Vitro

Tesmilifene may modulate the effects of 12(S)HETE in cancer cells, and indirectly, influence the susceptibility of cellular DNA to chemotherapy[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tesmilifene (DPPE, 20 mg/kg (s.c.) and 20 μg (icv in 5 μL)) potentiated seizures induced by both convulsants[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male BKTO mice (25-45 g)[2].
Dosage:	20 mg/kg (s.c.) and 20 μg (icv in 5 μL).
Administration:	S.C. and icv.
Result:	Potentiated seizures induced by both convulsants.

REFERENCES

[1]. Mark Vincent, et al. Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive, multi-drug resistant cells through its action on the p-glycoprotein pump. Med Hypotheses. 2006;66(4):715-31.

[2]. G Sturman, et al. Modulation of the intracellular and H3-histamine receptors and chemically-induced seizures in mice Agents Actions. 1994 Jun;41 Spec No:C68-9.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA